Itolizumab

Biocon’s Itolizumab Has Received The Drugs Controller General Of India’s (DCGI) Approval For Emergency Use In The Treatment Of Cytokine Release Syndrome (CRS) In Moderate To Severe ARDS (Acute Respiratory Distress Syndrome) Patients Due To COVID-19

How does it Work?

Itolizumab Mechanism Of Action Itolizumab’s unique mechanism of action of immunomodulation involves binding to the CD6 receptor and blocking the activation of T lymphocytes, which in turn suppresses the pro-inflammatory cytokines, thus reducing the cytokine storm and deadly inflammatory response.

Click here to download.